Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1948 1
1950 2
1951 3
1952 3
1953 3
1954 5
1955 8
1956 8
1957 11
1958 9
1959 18
1960 10
1961 9
1962 9
1963 12
1964 9
1965 10
1966 8
1967 4
1968 9
1969 7
1970 8
1971 4
1972 3
1973 7
1974 4
1975 8
1976 17
1977 17
1978 20
1979 10
1980 13
1981 12
1982 12
1983 26
1984 24
1985 23
1986 32
1987 22
1988 29
1989 35
1990 31
1991 28
1992 30
1993 33
1994 25
1995 23
1996 35
1997 33
1998 41
1999 28
2000 35
2001 35
2002 25
2003 27
2004 29
2005 39
2006 36
2007 37
2008 30
2009 23
2010 33
2011 35
2012 44
2013 54
2014 57
2015 77
2016 70
2017 84
2018 84
2019 96
2020 82
2021 77
2022 32
Text availability
Article attribute
Article type
Publication date

Search Results

1,803 results
Results by year
Filters applied: . Clear all
Page 1
Biotinidase Deficiency.
Wolf B. Wolf B. 2000 Mar 24 [updated 2016 Jun 9]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Mirzaa GM, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022. 2000 Mar 24 [updated 2016 Jun 9]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Mirzaa GM, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022. PMID: 20301497 Free Books & Documents. Review.
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.
Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D, Wilson KJ, DiPietro L, Fleming P, Palmer M, Hu MI, Wirth L, Brose MS, Ou SI, Taylor M, Garralda E, Miller S, Wolf B, Lengauer C, Guzi T, Evans EK. Subbiah V, et al. Among authors: wolf b. Cancer Discov. 2018 Jul;8(7):836-849. doi: 10.1158/2159-8290.CD-18-0338. Epub 2018 Apr 15. Cancer Discov. 2018. PMID: 29657135
Environment dominates over host genetics in shaping human gut microbiota.
Rothschild D, Weissbrod O, Barkan E, Kurilshikov A, Korem T, Zeevi D, Costea PI, Godneva A, Kalka IN, Bar N, Shilo S, Lador D, Vila AV, Zmora N, Pevsner-Fischer M, Israeli D, Kosower N, Malka G, Wolf BC, Avnit-Sagi T, Lotan-Pompan M, Weinberger A, Halpern Z, Carmi S, Fu J, Wijmenga C, Zhernakova A, Elinav E, Segal E. Rothschild D, et al. Among authors: wolf bc. Nature. 2018 Mar 8;555(7695):210-215. doi: 10.1038/nature25973. Epub 2018 Feb 28. Nature. 2018. PMID: 29489753
Personalized Postprandial Glucose Response-Targeting Diet Versus Mediterranean Diet for Glycemic Control in Prediabetes.
Ben-Yacov O, Godneva A, Rein M, Shilo S, Kolobkov D, Koren N, Cohen Dolev N, Travinsky Shmul T, Wolf BC, Kosower N, Sagiv K, Lotan-Pompan M, Zmora N, Weinberger A, Elinav E, Segal E. Ben-Yacov O, et al. Among authors: wolf bc. Diabetes Care. 2021 Sep;44(9):1980-1991. doi: 10.2337/dc21-0162. Epub 2021 Jul 23. Diabetes Care. 2021. PMID: 34301736 Clinical Trial.
A precision therapy against cancers driven by KIT/PDGFRA mutations.
Evans EK, Gardino AK, Kim JL, Hodous BL, Shutes A, Davis A, Zhu XJ, Schmidt-Kittler O, Wilson D, Wilson K, DiPietro L, Zhang Y, Brooijmans N, LaBranche TP, Wozniak A, Gebreyohannes YK, Schöffski P, Heinrich MC, DeAngelo DJ, Miller S, Wolf B, Kohl N, Guzi T, Lydon N, Boral A, Lengauer C. Evans EK, et al. Among authors: wolf b. Sci Transl Med. 2017 Nov 1;9(414):eaao1690. doi: 10.1126/scitranslmed.aao1690. Sci Transl Med. 2017. PMID: 29093181 Clinical Trial.
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.
Lisberg A, Cummings A, Goldman JW, Bornazyan K, Reese N, Wang T, Coluzzi P, Ledezma B, Mendenhall M, Hunt J, Wolf B, Jones B, Madrigal J, Horton J, Spiegel M, Carroll J, Gukasyan J, Williams T, Sauer L, Wells C, Hardy A, Linares P, Lim C, Ma L, Adame C, Garon EB. Lisberg A, et al. Among authors: wolf b. J Thorac Oncol. 2018 Aug;13(8):1138-1145. doi: 10.1016/j.jtho.2018.03.035. Epub 2018 Jun 1. J Thorac Oncol. 2018. PMID: 29874546 Free PMC article. Clinical Trial.
Dimethylcalcium.
Wolf BM, Stuhl C, Maichle-Mössmer C, Anwander R. Wolf BM, et al. J Am Chem Soc. 2018 Feb 14;140(6):2373-2383. doi: 10.1021/jacs.7b12984. Epub 2018 Feb 5. J Am Chem Soc. 2018. PMID: 29328671
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.
Heinrich MC, Jones RL, von Mehren M, Schöffski P, Serrano C, Kang YK, Cassier PA, Mir O, Eskens F, Tap WD, Rutkowski P, Chawla SP, Trent J, Tugnait M, Evans EK, Lauz T, Zhou T, Roche M, Wolf BB, Bauer S, George S. Heinrich MC, et al. Among authors: wolf bb. Lancet Oncol. 2020 Jul;21(7):935-946. doi: 10.1016/S1470-2045(20)30269-2. Lancet Oncol. 2020. PMID: 32615108 Clinical Trial.
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.
Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, Mazzaferro V, Trojan J, Zhu AX, Yoon JH, Sharma S, Lin ZZ, Chan SL, Faivre S, Feun LG, Yen CJ, Dufour JF, Palmer DH, Llovet JM, Manoogian M, Tugnait M, Stransky N, Hagel M, Kohl NE, Lengauer C, Sherwin CA, Schmidt-Kittler O, Hoeflich KP, Shi H, Wolf BB, Kang YK. Kim RD, et al. Among authors: wolf bb. Cancer Discov. 2019 Dec;9(12):1696-1707. doi: 10.1158/2159-8290.CD-19-0555. Epub 2019 Oct 1. Cancer Discov. 2019. PMID: 31575541 Free article. Clinical Trial.
1,803 results